COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ADAMTS-5 AND ADAM17

(19)

(11)

EP 3 237 619 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	10.03.2021 Bulletin 2021/10

(45)	Mention of the grant of the patent:
	21.10.2020 Bulletin 2020/43

(21)	Application number: 15872041.7

(22)	Date of filing: 23.12.2015

(51)

International Patent Classification (IPC):

C12N 15/113^(2010.01)
A61K 48/00^(2006.01)
A61P 19/02^(2006.01)

C12N 15/11^(2006.01)
A61P 29/00^(2006.01)

(86)	International application number:
	PCT/IB2015/002574

(87)	International publication number:
	WO 2016/103042 (30.06.2016 Gazette 2016/26)

(54)	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ADAMTS-5 AND ADAM17 ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HEMMUNG DER EXPRESSION VON ADAMTS-5 UND ADAM17 COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DE ADAMTS-5 ET ADAM17

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

25.12.2014 CN 201410828587
25.12.2014 CN 201410827650

(43)	Date of publication of application:
	01.11.2017 Bulletin 2017/44

(73)	Proprietor: Guangzhou Ribobio Co., Ltd.
	Guangzhou 510530 (CN)

(72)	Inventors:
	ZHANG, Bill, Biliang Guangzhou 510530 (CN) YANG, Xiuqun Guangzhou 510663 (CN)

(74)	Representative: Dehns
	St. Bride's House 10 Salisbury Square London EC4Y 8JD London EC4Y 8JD (GB)

(56)

References cited: :

CN-A- 102 181 446
CN-A- 104 560 997

CN-A- 104 498 498
CN-A- 104 560 999

RUO-HUA SONG ET AL: "Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5", ARTHRITIS & RHEUMATISM, vol. 56, no. 2, 1 February 2007 (2007-02-01), pages 575-585, XP055469796, US ISSN: 0004-3591, DOI: 10.1002/art.22334
SEKI SHOJI ET AL: "Effect of small interference RNA (siRNA) for ADAMTS5 on intervertebral disc degeneration in the rabbit anular needle-puncture model", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 6, 4 November 2009 (2009-11-04), page R166, XP021065267, ISSN: 1478-6354, DOI: 10.1186/AR2851
XIANGYU CHU ET AL: "Protective effect of lentivirus-mediated siRNA targeting ADAMTS-5 on cartilage degradation in a rat model of osteoarthritis", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 31, no. 5, 26 March 2013 (2013-03-26) , pages 1222-1228, XP055469613, GR ISSN: 1107-3756, DOI: 10.3892/ijmm.2013.1318
LOUISE A HURST ET AL: "siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 521, no. 1, 17 May 2012 (2012-05-17), pages 52-56, XP028495783, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2012.05.057 [retrieved on 2012-05-26]
DU QINGFENG ET AL.: 'Effects of aggrecanase-2 shRNA transfection on chondrocytes of rheumatoid arthritis patient leaded by lentivirus' CHINESE JOURNAL OF ORTHOPACDICS vol. 34, no. 9, 01 September 2014, pages 936 - 944, XP055456687 DOI: 10.3760/CMA.J.ISSN.0253?2352.2014.09.008

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).